Experimental combo for Hard-to-Treat cancers shows early promise but study halted

NCT ID NCT05580770

Terminated Disease control Sponsor: SpringWorks Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a combination of two oral drugs, mirdametinib and brimarafenib, in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumors. The study was terminated early, so results are limited, but the data may help guide future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mirdametinib and brimarafenib (BGB-3245) combination
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This was a very early (Phase 1/2a) study with only 23 participants, and it was terminated early. The combination may cause side effects and may not shrink tumors effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Calvary Mater Newcastle

Waratah, 2298, Australia
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Texas Oncology-Baylor Charles A. Sammons Cancer Center

Dallas, Texas, 75246, United States
UC San Diego Moores Cancer Center

La Jolla, California, 92093, United States
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
Yale-New Haven Hospital-Yale Cancer Center

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.